Anthony Flammia

Former Vice President & General Manager-Mergers & Acquisitions at The Medicines Co.

Anthony Flammia

Anthony Flammia

Former Vice President & General Manager-Mergers & Acquisitions at The Medicines Co.

Biography

Anthony Flammia is former Vice President & GM-Mergers & Acquisitions at The Medicines Co. He received an MBA from Fairleigh Dickinson University and an undergraduate degree from Florida Institute of Technology, Inc.

Overview
RelSci Relationships

1146

Relationships
RelSci Relationships are individuals Anthony Flammia likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Medical Officer (CMO) at Amryt Pharma PLC

Relationship likelihood: Strong

Executive Vice President, General Counsel & Secretary at The Medicines Co.

Relationship likelihood: Average

Chief Financial Officer & Treasurer at The Medicines Co.

Relationship likelihood: Average

Chief Executive Officer at Rempex Pharmaceuticals, Inc.

Relationship likelihood: Average

Head, Global Communications at The Medicines Co.

Relationship likelihood: Average

Global Launch Leader, Anti-Platelet Solutions at The Medicines Co.

Relationship likelihood: Average

Head, Global Contracting & Business Ethics at The Medicines Co.

Relationship likelihood: Average

Co-Founder at The Medicines Co.

Relationship likelihood: Average

President, Chief Executive Officer & Director at Ophthotech Corp.

Relationship likelihood: Average

Secretary & Vice President-General Counsel at Vero Biotech LLC

Relationship likelihood: Average

Paths to Anthony Flammia
Potential Connections via
Relationship Science
You
Anthony Flammia
Former Vice President & General Manager-Mergers & Acquisitions at The Medicines Co.
Career History
Vice President & General Manager-Mergers & Acquisitions
2003 - 2015

The Medicines Co We are a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. In the United States, we have three marketed products, Angiomax® (bivalirudin) for Injection, Cleviprex® (clevidipine) Injectable Emulsion, and Argatroban Injection, 50 mg per 50 mL†. We also have a pipeline of acute and intensive care hospital products in development, including three late-stage development product candidates, cangrelor, oritavancin and MDCO-157, and two early stage development product candidates, MDCO-2010 and MDCO-216. We believe that Angiomax, Cleviprex and our products in development possess favorable attributes that can satisfy unmet medical needs in the acute | intensive care hospital product market and offer, or, in the case of our products in development, have the potential to offer, improved performance to hospital businesses. The Company is publicly traded on the Nasdaq exchange under the ticker symbol MDCO. It was founded in 1996 and employs approximately 425 professionals.

Director, Technical Operations
Prior

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Global Supply Chain
Prior

Ernst & Young LLP engages in the provision of assurance, tax, transactions, and advisory services. It offers audit, business risk, technology, security risk, and human capital services. The company was founded by Arthur Young and Alwin C. Ernst in 1989 and is headquartered in New York, NY.

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Anthony Flammia. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Anthony Flammia's profile does not indicate a business or promotional relationship of any kind between RelSci and Anthony Flammia.